We confirmed previously reported alterations in several components of the NF-κB signaling, including TNFAIP3A (26%), MYD88 (12%), and BCL10 (7%), which were observed in 52 tumor specimens (Fig. 3B). This evidence concerns the gene MYD88 and neoplasm.